Patents Assigned to GPC Biotech AG
-
Patent number: 7629318Abstract: The present invention relates to compositions and methods for suppressing an immune response, e.g., by inhibiting class II MHC-mediated activation of T cells. The subject compounds and methods may be used to treat or prevent disorders such as rheumatoid arthritis and/or multiple sclerosis.Type: GrantFiled: March 24, 2003Date of Patent: December 8, 2009Assignee: GPC Biotech AGInventors: Zoltan Nagy, Tilmann Brandstetter
-
Patent number: 7605175Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: GrantFiled: April 7, 2004Date of Patent: October 20, 2009Assignees: GPC Biotech AG, GPC Biotech, Inc.Inventors: Frank Becker, Nicholas Bockovich, Jon H. Come, Arthur F. Kluge, Krishna K. Murthi, Chris Oalmann, Siya Ram, Zhongguo Wang
-
Patent number: 7521047Abstract: The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.Type: GrantFiled: November 15, 2001Date of Patent: April 21, 2009Assignees: GPC Biotech AG, Morphosys AGInventors: Zoltan Nagy, Christoph Brunner, Michael Tesar, Elisabeth Thomassen-Wolf, Robert Rauchenberger
-
Publication number: 20080272022Abstract: The invention relates to a packages and kits for dispensing and/or administering pharmaceuticals, particularly for dispensing and/or administering combinations of different formulations.Type: ApplicationFiled: July 13, 2005Publication date: November 6, 2008Applicant: GPC BIOTECH AGInventors: Shirishkumar B. Kulkarni, Hemanshu S. Shah
-
Publication number: 20080207677Abstract: The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.Type: ApplicationFiled: January 2, 2006Publication date: August 28, 2008Applicant: GPC BIOTECH AGInventors: Stefan Muller, Wilfried Schwab, Bert Klebl, Doris Hafenbradl, Edmund Hoppe, Zoltan Horvath, Gyorgy Keri, Zoltan Varga, Laszlo Orfi, Jeno Marosfalvi, Gerhard Muller
-
Patent number: 7341717Abstract: The present invention relates to the human cellular protein glutathione peroxidase-gastrointestinal as a target for medical intervention against Hepatitis C virus (HCV) infections. Furthermore, the present invention relates to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections and a method for detecting Hepatitis C virus infections in an individual or in cells. Also compositions, compounds, nucleic acid molecules (such as aptamers), mono- or polyclonal antibodies are disclosed which are effective for the treatment of HCV infections, and methods for prophylaxis and/or treatment of Hepatitis C virus infections or for the regulation of Hepatitis C virus production are disclosed.Type: GrantFiled: November 26, 2003Date of Patent: March 11, 2008Assignee: GPC Biotech AGInventors: Thomas Herget, Matthew Cotten, Sabine Obert, Bert Klebl
-
Publication number: 20080058411Abstract: The instant invention relates to methods, pharmaceutical compositions and packaged pharmaceuticals for treating resistant or refractory tumors by administering platinum-based compounds.Type: ApplicationFiled: February 18, 2005Publication date: March 6, 2008Applicant: GPC Biotech AGInventors: Maureen Caligiuri, Katja Wosikowski-Buters, Anna Maria Casazza
-
Publication number: 20070275962Abstract: Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.Type: ApplicationFiled: September 10, 2004Publication date: November 29, 2007Applicant: GPC BIOTECH AGInventors: Anil Koul, Bert Klebl, Gerhard Muller, Andrea Missio, Wilfried Schwab, Doris Hafenbradl, Lars Neumann, Marc-Nicola Sommer, Stefan Muller, Edmund Hoppe, Achim Freisleben, Alexander Backes, Christian Hartung, Beatrice Felber, Birgit Zech, Ola Engkvist, Gyorgy Keri, Laszlo Orfi, Peter Banhegyi, Zoltan Greff, Zoltan Horvath, Zoltan Varga, Peter Marko, Janos Pato, Istvan Szabadkai, Zsolt Szekelyhid, Frigyes Waczek
-
Publication number: 20070123537Abstract: The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.Type: ApplicationFiled: October 5, 2004Publication date: May 31, 2007Applicant: GPC Biotech AGInventor: Thomas Herget
-
Publication number: 20070086998Abstract: The instant invention relates to methods, compositions, uses related to the compositions and pharmaceutical packages for treating a disorder involving cells expressing MHC class II antigens using a combination of a human antibody-based antigen-binding domain that binds to a human Class II MHC molecule, and an antibody-based antigen-binding domain that binds to a cell surface receptor. Such disorders include cell proliferative disorders like lymphomas, leukemias, and certain solid tumors including melanomas, as well as disorders characterized by unwanted activation of immune cells like rheumatoid arthritis and multiple sclerosis.Type: ApplicationFiled: September 9, 2004Publication date: April 19, 2007Applicant: GPC Biotech AGInventor: Zoltan Nagy
-
Patent number: 7135550Abstract: The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.Type: GrantFiled: September 3, 2002Date of Patent: November 14, 2006Assignees: GPC Biotech Inc., GPC Biotech AGInventors: Jon H. Come, Frank Becker, Nikolai A. Kley, Christoph Reichel
-
Publication number: 20060151574Abstract: The present invention relates generally to chemical compounds and substances which are effective against Hepatitis C virus (HCV) infections. Moreover, the present invention relates to compositions comprising said compounds and/or substances, to methods for preventing HCV infections as well use of the compounds and/or substances for the preparation of compositions useful for the prophylaxis and/or treatment of HCV infections.Type: ApplicationFiled: December 1, 2003Publication date: July 13, 2006Applicant: GPC Biotech AGInventors: Thomas Herget, Bert Klebl
-
Publication number: 20060004077Abstract: The present invention relates to compositions and methods for suppressing an immune response, e.g., by inhibiting class II MHC-mediated activation of T cells. The subject compounds and methods may be used to treat or prevent disorders such as rheumatoid arthritis and/or multiple sclerosis.Type: ApplicationFiled: March 24, 2003Publication date: January 5, 2006Applicant: GPC Biotech AGInventors: Zoltan Nagy, Tilmann Brandstetter
-
Publication number: 20050090471Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: ApplicationFiled: October 15, 2002Publication date: April 28, 2005Applicants: GPC Biotech, Inc, GPC Biotech AGInventors: Nicholas Bockovich, Arthur Kluge, Siya Ram, Zhongguo Wang, Chris Oalmann, Krishna Murthi, Frank Becker
-
Publication number: 20040266854Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: ApplicationFiled: April 7, 2004Publication date: December 30, 2004Applicants: GPC Biotech, Inc., GPC Biotech AGInventors: Frank Becker, Nicholas Bockovich, Jon H. Come, Arthur Kluge, Krishna K. Murthi, Chris Oalmann, Siya Ram, Zhongguo Wang
-
Patent number: 6753329Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: GrantFiled: December 17, 2002Date of Patent: June 22, 2004Assignees: GPC Biotech Inc., GPC Biotech AGInventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Frank Becker
-
Patent number: 6658324Abstract: A plant is provided for rapid pick and place operations, enabling automated systems that return to at least one approximately fixed position to run faster than the rate of conventional systems. The plant utilises a novel combination of robotic design, linear motor technology, and control software. A system and method if provided for the rapid production of high-density arrays of biologically active substances.Type: GrantFiled: September 21, 2001Date of Patent: December 2, 2003Assignee: GPC Biotech AGInventors: David Bancroft, Markus Kietzmann